Panbela Therapeutics Past Earnings Performance
Past criteria checks 0/6
Panbela Therapeutics's earnings have been declining at an average annual rate of -43.7%, while the Biotechs industry saw earnings growing at 15% annually.
Key information
-43.7%
Earnings growth rate
n/a
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Panbela Therapeutics dips 24% on pricing $6M public offering
Sep 30Panbela Therapeutics GAAP EPS of -$1.51
Aug 15Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth
Feb 18Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication
Jan 06Will Panbela Therapeutics (NASDAQ:PBLA) Spend Its Cash Wisely?
Nov 02Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth
Jul 15Panbela Therapeutics to join Russell Microcap Index
Jun 09We Think Panbela Therapeutics (NASDAQ:PBLA) Can Afford To Drive Business Growth
Mar 29Revenue & Expenses Breakdown
How Panbela Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -36 | 5 | 23 |
31 Dec 23 | 0 | -34 | 5 | 21 |
30 Sep 23 | 0 | -24 | 6 | 18 |
30 Jun 23 | 0 | -20 | 6 | 14 |
31 Mar 23 | 0 | -36 | 6 | 12 |
31 Dec 22 | 0 | -35 | 6 | 10 |
30 Sep 22 | 0 | -34 | 6 | 9 |
30 Jun 22 | 0 | -31 | 5 | 8 |
31 Mar 22 | 0 | -12 | 5 | 7 |
31 Dec 21 | 0 | -10 | 5 | 5 |
30 Sep 21 | 0 | -7 | 4 | 4 |
30 Jun 21 | 0 | -7 | 5 | 4 |
31 Mar 21 | 0 | -5 | 4 | 3 |
31 Dec 20 | 0 | -5 | 3 | 3 |
30 Sep 20 | 0 | -5 | 3 | 3 |
30 Jun 20 | 0 | -5 | 2 | 3 |
31 Mar 20 | 0 | -6 | 2 | 3 |
31 Dec 19 | 0 | -6 | 2 | 2 |
30 Sep 19 | 0 | -6 | 2 | 2 |
30 Jun 19 | 0 | -6 | 2 | 2 |
31 Mar 19 | 0 | -6 | 2 | 2 |
31 Dec 18 | 0 | -6 | 2 | 2 |
30 Sep 18 | 0 | -7 | 3 | 2 |
30 Jun 18 | 0 | -8 | 3 | 2 |
31 Mar 18 | 0 | -7 | 3 | 2 |
31 Dec 17 | 0 | -10 | 3 | 3 |
30 Sep 17 | 0 | -10 | 4 | 3 |
30 Jun 17 | 0 | -10 | 4 | 3 |
31 Mar 17 | 0 | -10 | 3 | 3 |
31 Dec 16 | 0 | -5 | 3 | 3 |
30 Sep 16 | 0 | -4 | 1 | 3 |
30 Jun 16 | 0 | -3 | 1 | 2 |
31 Mar 16 | 0 | -4 | 2 | 2 |
31 Dec 15 | 0 | -5 | 2 | 3 |
30 Sep 15 | 0 | -5 | 2 | 3 |
30 Jun 15 | 0 | -6 | 2 | 3 |
31 Mar 15 | 0 | -5 | 2 | 3 |
31 Dec 14 | 0 | -4 | 1 | 2 |
Quality Earnings: PBLA is currently unprofitable.
Growing Profit Margin: PBLA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PBLA is unprofitable, and losses have increased over the past 5 years at a rate of 43.7% per year.
Accelerating Growth: Unable to compare PBLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PBLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: PBLA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.